Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares are trading +0.35% thus far today and have traded in the range of 21.84 – 22.79 during the current session. In order to take a look at where the stock might headed longer term, we can also look at different sets of data. Sell-side research firms currently have a consensus one year price target of $43.58 on the stock according to First Call. This number can often vary from the Zacks or FactSet mean targets. The sell-side analysts are projecting earnings per share of $2.06 for the next fiscal quarter. For the current year, analysts are predicting earnings of $6.53 per share according to First Call.
Stock Technicals in Focus
In looking at where the stock is trading on a technical level, the stock is trading -15.22% away from its 50 day moving average of $26.86. Based on the most recent available data, the equity is -87.34% off of its 52-week high of $179.83 and +22.75% away from its 52-week low which is $18.55. In taking a look at the company’s valuation, the firm’s price to earnings ratio stands at N/A. This is a crucial indicator investors watch as higher ratios compared to peers, would suggest higher future earnings growth potential for the stock. The price to current year EPS estimates from research analysts currently stands at 3.49. In looking further ahead, potential investors should note that the company’s price to next year’s EPS estimates is 2.96.
Today, the stock opened at $22.49 and the last bid at the time of writing stood at $22.77. During the session thus far, the equity dipped down to $21.84 and touched $22.79 as the high point. Valeant Pharmaceuticals Interna has a market cap of 7.91B and has seen an average daily volume of 22608000 over the past three months.
The Wall Street analysts who cover Bed Bath & Beyond Inc. (NASDAQ:BBBY) shares are providing price target projections on the company. They project that the shares will move to $43.75 within the upcoming year. The number they've arrived at is calculated by Zacks.com, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $55 and the lowest is at $35 for the stock. This number may be different from what First Call has published for the consensus target estimate. Analysts that routinely cover the company may use varying techniques in order to create a future target price. Because of the different methods that analysts can use, targets may differ greatly between analysts.
Analyst Ratings In View
Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. Bed Bath & Beyond Inc. (NASDAQ:BBBY)'s shares currently have an ABR of 3.14. A 1 rating would point to a Strong Buy, and a score of 5 would signify a Strong Sell rating. The average broker rating assists investors by providing them with a general feel for analyst sentiment on company shares. The success of analyst predictions can be tracked for institutional investors through First Call. Retail investors can use tools such as TipRanks or Marketbeat in order to track analyst performance.
During this fiscal period, Street analysts are projecting $1.01 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2016-08-31, Bed Bath & Beyond Inc. (NASDAQ:BBBY) dialed in an EPS of $1.11, creating a Surprise Factor of -5.13% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2017-01-05, the date when Bed Bath & Beyond Inc. (NASDAQ:BBBY) will release their quarterly results. A surprise factor in either direction may result in significant stock movement immediately and in the days following the release. Firms that consistently miss expectations can experience a downtrend over time. Whereas stocks that consistently outperform analyst expectations, can often see positive stock movement.